Dr. Michael Grunwald ASH 2018 Risk Assessment and Treatment Myelofibrosis Patients at Community Oncology Practices in the U.S.

Patient Reported Financial Toxicity in AML & MPN

Third in ASH 2018 Series

by David Wallace

Dr. Michael Grunwald is the Director, Leukemia Division, Department of Hematologic Oncology and Blood Disorders at Levine Cancer Institute in Charlotte, NC.  Dr. Grunwald and David Wallace, PV Reporter, discuss multiple topics during ASH 2018 conference.

The ASH abstracts we discussed can be found herePatient Reported Financial Toxicity in Acute Leukemia and Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States.


error: Content is protected !